


**University of Florida  
Curriculum Vitae**

  
7/26/18

**Date Prepared:** July 26, 2018

**Name:** Dennie Vance Jones, Jr., MD

**Office Address:** North Florida/South Georgia Veterans Health System  
Section of Hematology/Oncology  
1601 SW Archer Road  
Gainesville, FL 32608-1135

**Home Address:** 601 Centennial Lane  
Lexington, KY 40502

**Office Phone:** (352) 548-6000, x4320

**Office Email:** [Dennie.Jones@VA.gov](mailto:Dennie.Jones@VA.gov)  
[Dennie.Jones@medicine.ufl.edu](mailto:Dennie.Jones@medicine.ufl.edu)

**Home Email:** [d3m2jones@gmail.com](mailto:d3m2jones@gmail.com)

**Place of Birth:** Chicago, Illinois, USA

**Citizenship:** United States of America (by birth)

**Education**

1981	BA	Biology	Washington University, St. Louis, MO
1985	MD	Medicine	Washington University Medical School

**Postdoctoral Training**

06/85—06/86	Intern (PGY-1)	Internal Medicine	Baylor College of Medicine, Houston, TX
07/86—06/88	Resident (PGY 2-3)	Internal Medicine	Baylor College of Medicine
07/88—06/91	Fellow (PGY 4-6)	Medical Oncology	University of Texas MD Anderson Cancer Center, Houston, TX

### **Board Certifications**

Sept. 15, 1988	Internal Medicine
Nov. 5, 1991	Medical Oncology
Nov. 5, 2001	Medical Oncology
Nov. 16, 2011	Medical Oncology

### **Medical Licensure**

Florida	ME 126374 (12-9-15 to present)
Ohio	127122 (8-1-2015 to 9-30-2016)
Massachusetts	216036 (10-1-2014 to present)
Kentucky	44428 (5-1-2011 to present)
New Mexico	MD2005-0555 (8-1-2005 to 7-31-2012)
Texas	H1002 (8-1-1988 - 2-28-2006)

### **Faculty Academic Appointments**

07/91—08/92	Faculty Associate and Staff Attending	Medical Oncology	University of Texas MD Anderson Cancer Center
09/92—05/96	Assistant Professor, Assistant Attending	Medical Oncology	University of Texas MD Anderson Cancer Center
08/98—08/01	Assistant Professor	Medical Oncology	University of Texas Medical Branch (UTMB), Galveston, TX
09/01—07/05	Associate Professor	Medical Oncology	University of Texas Medical Branch, Galveston
08/05—06/07	Associate Professor	Medical Oncology	University of New Mexico (UNM), Albuquerque, NM
07/07—07/09	Associate Professor with Tenure	Medical Oncology	University of New Mexico
08/09—03/11	Professor with Tenure	Medical Oncology	University of New Mexico
04/11—08/14	Professor with Tenure	Medical Oncology	University of Kentucky (UK), Lexington, Ky

08/14—06/15	Lecturer	Medicine	Harvard Medical School (HMS), Boston, MA
11/15-present	Professor	Hematology/Oncology	University of Florida Gainesville, FL

### **Appointments at Hospitals/Affiliated Institutions**

07/91—08/92	Staff Attending	Medical Oncology, Division of University of Texas MD Gastrointestinal (GI) Oncology and Digestive Diseases	Anderson Cancer Center
09/92—05/96	Assistant Attending	Medical Oncology, Division of University of Texas MD Gastrointestinal Oncology and Digestive Diseases	Anderson Cancer Center
08/98—07/05	Faculty Attending	Medicine, Division of Hematology and Oncology	University of Texas Medical Branch, Galveston
08/05—03/11	Faculty Attending	Medicine, Division of Hematology and Oncology	University of New Mexico
07/99—03/11	Faculty Attending	Medicine, Division of Hematology and Oncology	University of New Mexico at Lovelace Medical Center, Albuquerque, NM
04/11—08/14	Faculty Attending	Medicine, Division of Medical Oncology	University of Kentucky
07/12—12/12	Faculty Attending	Medicine, Division of Medical Oncology	University of Kentucky Markey Cancer Center Clinic at Georgetown Community Hospital, Georgetown, KY
07/12—05/14	Faculty Attending	Medicine, Division of Medical Oncology	University of Kentucky Markey Cancer Center Clinic at Harrison Memorial Hospital, Cynthiana, KY
08/14—06/15	Associate Physician	Division of Oncology	Brigham and Women's Hospital, Boston, MA
08/14—06/15	Attending	Medical Oncology	Dana Farber Cancer Institute (DFCI), Boston, MA
08/15—11/15	Staff Physician	Medical Oncology	Baptist Health Madisonville (locum tenens)
11/15—present	Faculty Attending	Section of Hematology/Oncology	North Florida/South Georgia Veterans Health System (Gainesville, FL)
11/15—present	Faculty Attending	Division of Hematology and Oncology	University of Florida (Gainesville, FL)

### **Other Professional Positions**

1996—1998	Clinical Scientist	Genentech, Inc., South San Francisco, CA
2000-2001	Scientific Advisory Board	Cell Therapeutics, Inc., Seattle, WA
2002	Scientific Advisory Board	Ligand Pharmaceuticals, La Jolla, CA
2003	Scientific Advisory Board	Millennium Pharmaceuticals, Inc., Cambridge, MA
2004	Scientific Advisory Board	Praecis Pharmaceuticals, Waltham, MA
2005—2007	Scientific Advisory Board	Sanofi-Aventis Oncology Bridgewater, NJ
2005—2007	Scientific Advisory Board	Bristol-Myers Squibb, Inc. New York, NY
2005—2011	Scientific Advisory Board	Genentech, Inc., South San Francisco, CA
2005—2012	Scientific Advisory Board	Lilly Oncology, Indianapolis, IN
2008, 2014	Scientific Advisory Board	Amgen, Inc., Thousand Oaks, CA
2014	Scientific Advisory Board	Bayer Healthcare, Inc., Whippany, NJ

### **Major Administrative Leadership Positions**

#### **Local**

11/98—09/00	Director, Medical Oncology Fellowship Program	University of Texas Medical Branch, Galveston
05/99—07/05	Director, Clinical Trials Office	University of Texas Medical Branch
09/99—07/01	Acting Chief, Division of Hematology and Oncology	University of Texas Medical Branch
08/00—03/03	Medical Director, Hematology and Oncology Outpatient Clinic	University of Texas Medical Branch
07/01—07/05	Deputy Chief, Division of Hematology and Oncology	University of Texas Medical Branch
11/02—07/05	Director, Medical Oncology Fellowship Program	University of Texas Medical Branch
08/06—01/09	Director, Clinical Trials Office	University of New Mexico
08/06—03/11	Medical Director, New Mexico Cancer Care Alliance	University of New Mexico
07/07—03/11	Chief, Section of Thoracic Oncology	University of New Mexico
01/09—03/11	Director, Clinical Protocol, Data Management, and Medical Informatics Program	University of New Mexico
01/09—03/11	Director, Inpatient Oncology Service	University of New Mexico
04/11—12/13	Deputy Director, Markey Cancer Center	University of Kentucky
04/11—03/14	Medical Director, Markey Cancer Center Affiliate Network (MCCAN)	University of Kentucky

08/11—07/12	Acting Chief, Division of Medical Oncology	University of Kentucky
08/14—06/15	Chief, Division of Hematology-Oncology	Dana-Farber Cancer Institute at St. Elizabeth's Medical Center (SEMC), Brighton, MA
08/14—06/17	Hematology/Oncology Unit Medical Director	Dana-Farber Cancer Institute at St. Elizabeth's Medical Center
11/15—05/18	Chief, Section of Hematology/Oncology	North Georgia/South Florida Veterans Health System, Gainesville, FL

### **Committee Service**

#### **Local**

1994—1996	Surveillance Committee (Protocol Scientific Review Committee), member	University of Texas MD Anderson Cancer Center
1998—2005	Cancer Committee of the Medical Staff, member	University of Texas Medical Branch, Galveston
2002—2005	Cancer Center Development Committee, member	University of Texas Medical Branch
2003—2005	Institutional Ethics Committee, member	University of Texas Medical Branch
2003	Transfusion Committee, member	University of Texas Medical Branch
2004—2005	Residency Review Committee, member	University of Texas Medical Branch
2004—2005	Cancer Steering Committee ( <i>ad hoc</i> ), member	University of Texas Medical Branch
2005—2011	Protocol Specific Research Support Committee, member	University of New Mexico
2007—2011	Human Research Review Committee, member	University of New Mexico
2007—2011	Medical Scientific Review Committee (New Mexico Cancer Care Alliance), member	University of New Mexico
2007	Black Faculty Association, Vice President	University of New Mexico
2009—2011	Adult Inpatient Medicine Committee, member	University of New Mexico
2009—2011	Faculty Senate, member	University of New Mexico
2010	Oncology Care Group, member	University of New Mexico
2010—2011	Surface Foundation Endowed Professorships Search Committee, member	University of New Mexico
2011—2014	Markey Cancer Center Data Safety and Monitoring Committee, member	University of Kentucky
2011—2014	Thoracic Oncology Clinical Care and Research Team, member	University of Kentucky
2012—2014	Institutional Review Board, <i>ad hoc</i> reviewer	University of Kentucky
2013—2014	Urologic Oncology Clinical Care and Research Team, member	University of Kentucky
2013—2014	Markey Affiliate Network Case Conference Series, member	University of Kentucky

2013—2014	Center for Clinical and Translational Science Drug Discovery and Development Therapeutic Advisory Committee, member	University of Kentucky
2013—2014	Internal Medicine Appointment, Promotion and Tenure Review Committee, member	University of Kentucky

### **Professional Societies**

1991— present	American Society of Clinical Oncology	Member
1991— present	American Medical Association	Member
2000— present	American College of Physicians	Member
2012— present	Southern Society of Clinical Investigation	Member
2016— present	American Association of Cancer Research	Member

### **Grant Review Activities**

2010—2011	National Institutes of Health (NIH) Loan Repayment Program, <i>ad hoc</i> Reviewer	Ad Hoc Member
2011	National Cancer Institute (NCI)- American Recovery and Reinvestment Act (ARRA) P30 Biomedical Research Core Centers Review Committee	Ad Hoc Member
2011—2012	Kentucky Lung Cancer Research Program Grant Review Panel	Member
2012—2013	NIH SPORE (Specialized Program of Research Excellence) Study Section	Ad Hoc Member
2013—2014	UK Center for Clinical and Translational Science Internal Grant Review Committee	Member

### **Editorial Activities**

#### ***Ad hoc Reviewer***

The Open Drug Resistance Journal  
Oncology Net Guide  
Internet Journal of Oncology  
Head and Neck Cancer  
Oncology Discovery  
Journal of Oncopathology

## Other Editorial Roles

2012— present	Editorial Board	Journal of Oncology Practice
2012— Present	Editorial Board	Oncology Case Reports
2014— present	Editorial Board	Hyperplasia of Cancer
2014— present	Editorial Board	Developments in Clinical Oncology

## Honors and Prizes

1977- 1981	Chancellor's Honorary Scholar	Washington University	Scholarship
1984	National Medical Fellowship	Washington University	Scholarship
1990	American Cancer Society Fellowship	American Cancer Society	Scholarship

## Report of Funded and Unfunded Projects

### Funding Information

#### Past—Federal Funding

2014- present	A Phase II Trial of TAS-102 (Lonsurf) in Previously Treated Unresectable or Metastatic Squamous Cell Carcinoma of the Lung
	UF-STO-LUNG-003/ IIT-USA-0113
	Site PI
	The primary objective is to determine the progression-free survival, in months, of subjects receiving TAS 102 for the treatment of unresectable or metastatic recurrent squamous cell lung cancers.
2014- present	A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients with Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung
	UF-STO-LUNG-002/ W1211924
	Site PI
	The primary objective is to identify the maximum tolerated dose of PF-05212384 in combination with paclitaxel and carboplatin in subjects with NSCLC.

2000-2013	Minority-Based Community Clinical Oncology Program Project Title: New Mexico Minority-Based Community Clinical Oncology Program (Claire Verschraegen, PI)
	2U10 CA086780
	Co-PI
	The goal was to provide access to the community to oncology clinical trials. New Mexico is a “minority majority” state, in which Hispanics and Native Americans comprise the majority of the population. This was (is) a unique opportunity to provide clinical trials to populations that usually are under-represented in clinical research
2001-2004	Research Supplements for Under Represented Minorities Program Project Title: Evaluation of Chemotherapy Claims for Breast Cancer (Xianglin Du, PI)
	3 R01 CA90626-02S1
	Coinvestigator—role was to provide data analysis and participate in writing the manuscript
	The major goal of the study was to use Medicare claims to evaluate the use of adjuvant chemotherapy in elderly women
2008-2009	Project Title: A Phase I/II Study of MS-275 in Combination with 5-Azacytidine in Patients with Recurrent Advanced Non-Small Cell Lung Cancer (Charles Rudin, PI)
	5 R21 CA126264-02
	Site-PI
	The goal of this clinical trial was to provide proof of principle for chromatin modification therapy in nonsmall cell lung cancer
2010-2011	Project Title: New Mexico Center for Advancement of Research, Engagement and Science on Health Disparities (Robert Williams, PI)
	1P20 MD4811-01
	Co-Investigator and Associate Director
	The goal of this funded project was to enhance minority (Hispanic and Native American) participation in community outreach and community-based research. The focus of this project was beyond medical oncology exclusively, including other aspects of medicine and medical education, though I was responsible for coordinating cancer outreach.
2013-2014	Project Title: Aberrant Signal Transduction and Epigenetic Changes in Lung Cancer Cells: A Phase II Study Of Peri-Operative 5-Azacytidine And MS-275 (Entinostat) In Patients With Surgically-Resectable Non Small Cell Lung Cancer (CTEP LOI# 9431) (Mathewos Tessema, PI)
	1 R21 CA161561-01A1
	Site PI
	The goal of this clinical trial is to provide proof of principle for chromatin modification as a potential chemopreventive regimen in lung cancer, investigation aberrant gene promoter hypermethylation as an intermediate biomarker.



**Past—Pharmaceutical Company Funding (all as site PI)**

2016-2018	A randomized, open-label, multi-center, international phase 2 study of TAS-114 in combination with S-1 in patients with advanced or metastatic non-small cell lung cancer
1998-1999	Genetics Institute, “A Phase I Open-Label, Sequential Dose-Escalating Safety Study of Recombinant Human Interleukin Eleven (RhIL-11) to Reduce Mucositis given Concurrently with and after 5 Consecutive day Intravenous Bolus 5-Flouracil/Leucovorin Chemotherapy in Patients with Solid Tumors”
1998-2000	Zeneca Pharmaceuticals, “A Double-Blind, Randomized, Multicenter Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long-acting ICI 182, 780) with 20mg of Nolvadex (Tamoxifen) in Postmenopausal women with Advanced Breast”
1999-2000	Bristol Myers Squibb, “Quality of Life Study Comparing Carboplatin vs. Cisplatin Combination Chemotherapy Treatment in Ovarian Cancer”
1999-2000	SmithKline Beecham, “An Open-Label, Multicenter, Randomized, Phase II Study of 5 Day Oral Topotecan vs. 21 Day Oral Topotecan vs. CPT-11 (Irinotecan) for Second-Line therapy in Patients with Colorectal Carcinoma”
1999-2000	Theradex, Inc., “A Phase II Trial of Paclitaxel (Taxol) Administered as a Weekly One Hour Infusion in Patients with Advanced Esophageal Cancer”
1999-2000	Schering Plough, “Phase II/III Trial of SCH 54031 PEG Interferon alfa-2b (PEG Intron) vs. INTRON A as Adjuvant therapy for Melanoma”
1999-2001	SmithKline Beecham, “An Open-Label, Multicenter, Randomized, Phase II Study of Topotecan/Paclitaxel vs. Etoposide/Cisplatin as First-Line Therapy for Patients with Extensive Disease Small Cell Lung Cancer”
1999-2001	SmithKline Beecham, “An Open-Label, Multicenter, Randomized, Phase III Comparator Study of Oral Topotecan vs. Intravenous Topotecan for Second-Line Therapy In Patients with SCLC Who Have Relapsed Greater than or Equal to 90 Days After Completion of First-Line Therapy”
1999-2001	Prologue, “A Compassionate Use Study of Oxaliplatin for Previously Treated Colorectal Cancer Patients”
1999-2001	Eli Lilly & Co., “A Phase III Study of Gemcitabine Plus Paclitaxel vs. Paclitaxel in Patients with Unresectable, Locally Recurrent or Metastatic Breast Cancer”

2000-2002	SmithKline Beecham, "A Phase I Study of Combination Therapy with Topotecan, Gemcitabine and Paclitaxel in Patients with Advanced Solid Tumors"
2000-2003	Amgen, "A Phase II Study of Docetaxel and Vinorelbine in Advanced Non-Small Cell Lung Carcinoma"
2000-2002	Prologue, "Phase I/II Trial of Eloxatin (Oxaliplatin) and CPT-11 Administered Once Every Three Weeks to Patients with Metastatic Colorectal Cancer"
2003-2005	Cell Therapeutics, Inc., "A Phase II Trial of Arsenic Trioxide (Trisenox) in Patients with Advanced Nonsmall Cell Carcinomas of the Lung"
2003-2005	Cell Therapeutics, Inc., "A Phase II Trial of Arsenic Trioxide (Trisenox) in Patients with Advanced Carcinomas of the Breast"
2004-2005	Lilly Oncology, "A Multicenter, Randomized, Phase II Trial of Gemcitabine Plus 5FU/Folinic Acid (FFG) vs. Oxaliplatin Plus 5FU/Folinic Acid (FOLFOX 4) as Therapy for Patients with Metastatic Colorectal Cancer"
2004-2005	Amgen, "5-Flourouracil, Oxaliplatin, Irinotecan, and Leucovorin (FOIL) Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First- or Second-line Treatment in Subjects with Locally Advanced or Metastatic Colon Cancer"
2004-2005	Bristol Myers Squibb, "A Phase III Randomized, Open-Label, Multicenter Study of Irinotecan and Cetuximab vs. Irinotecan as Second-Line Treatment in Patients with Metastatic, EGFR-Positive Colorectal Carcinoma (Protocol CA225006)"
2004-2005	Astra-Zeneca, "A Phase II Protocol Of Neoadjuvant Therapy With Fulvestrant (Faslodex) In Patients With Locally-Advanced, Hormone Receptor-Positive Carcinoma Of The Breast"
2004-2008	Taiho Pharma USA, "An Open-Label, Non-Randomized, Multicenter, Three Stage, Phase 2 Study Of S-1 In Combination With Cisplatin As 1st Line Therapy For Patients With Advanced Non-Small Cell Lung Cancer (Stage IIIb/Stage IV)"
2005-2008	SmithKline Beecham, INST 0529C, "Phase I study of concurrent radiotherapy with weekly Topotecan for primary treatment of inoperable localized non-small cell lung cancer (NSCLC) (Stage I to IIIA)"
2006-2010	Genentech, Inc. "A Non-Randomized Phase II Protocol Of Erlotinib Followed by Standard Platinum-Based Chemotherapy Patients With Newly Diagnosed, Advanced Non-Small Cell

	Carcinoma Of The Lung”
2006-2011	Amgen, “A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)”
2006-2011	Pharmacyclics PCYC 0228: “Phase II trial of Motexafin Gadolinium and Pemetrexed (Alimta) for Second Line Treatment in Patients with Non-Small Cell Lung Cancer”
2006-2011	Eli Lilly H3E-MC-JMHO: “A Randomized Phase 3 Trial of ALIMTA (Pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer (GALES Study)”
2006-2011	OSI, Pharmaceuticals. OSI 774-302: “A multi-center, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA Non-small Cell Lung Carcinoma who have EGFR-positive Tumors”
2007-2008	Vioquest 7059, “A Phase I/IIa, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sodium Stibogluconate in Combination with Interferon Alpha-2b for Patients with Advanced Malignancies”
2007-2012	PPD/Genentech, Inc. AVF3991n: “An observational study of Avastin (bevacizumab) in combination with chemotherapy for treatment of metastatic or locally advanced and unresectable colorectal cancer, locally advanced or metastatic non-small cell lung (excluding predominant squamous cell histology), or locally recurrent or metastatic breast cancer (ARIES)”
2009-2010	Regeneron VGFT-ST-0708: “A Phase 1/2 Study of Aflibercept Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Carcinoma”
2012-2013	Genentech, Inc. (OAM4971g): “A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMab) in Combination with Tarceva® (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Standard Chemotherapy for Advanced or Metastatic Disease”
2012-2013	Incyte, Inc. (INCB18424-262): “A randomized Phase 2 study of Ruxolitinib Efficacy and safety in combination with Capecitabine for subjects with recurrent or treatment refractory metastatic Pancreatic cancer (The RECAP trial)”
2012-	Oncothyreon Inc. (PX-866-003): “Phase 1/2 study of PX-866 and cetuximab”

2013	
2012-2013	PrECOG: (MO22097 E0502): "An Open-Label, Randomized, Phase IIIb Trial Evaluating The Efficacy And Safety Of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression Of Disease In Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After First-Line Treatment With Bevacizumab Plus A Platinum Doublet-Containing Chemotherapy"
2013-2014	Cancer Research and Biostatistics Consortium/Novartis, "Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer"

### Recent Unfunded Projects

2012-2014      11-LUN-90-MCC: A Non-Randomized Phase II Protocol Of Irinotecan For Subjects With Previously Treated, Advanced ISG15 – Positive Non-Small Cell Carcinoma Of The Lung

Interferon-Stimulated Gene-15 (ISG15) is a 15 kDa ubiquitin-like protein which is induced by interferons alpha and beta, and is a member of the ubiquitin-like protein superfamily. ISG15 overexpression and conjugation to its target proteins may lead to their stabilization. ISG15 appears to be associated with a decrease in the level of polyubiquitinated proteins, and to a negative regulation of the ubiquitin/26S proteasome pathway. The potential importance of this lies in the fact that 26S proteasome function appears to correlate with camptothecin resistance. Camptothecin appears to lead to a down-regulation of its target, topoisomerase 1, and this in turn leads to the development of resistance to camptothecin; this process can be inhibited *in vitro* by inhibiting the function of the 26S proteasome, with the restoration of camptothecin sensitivity. A subset of nonsmall cell lung cancers over-express ISG-15 and this correlates with sensitivity to irinotecan and toloptecan *in vitro*. The purpose of this phase II trial is to determine if ISG-15 expression is correlated with irinotecan sensitivity in nonsmall cell lung cancer. This project, where I served as PI until my departure, is ongoing, and I maintain overall scientific control. My responsibility will be to analyze the data as it comes in and in summary, and to produce the manuscript once accrual is complete and the data has been fully analyzed and cleaned.

## Report of Local Teaching and Training

### Teaching of Students in Courses--University of Kentucky

2013	Chemistry 580: DNA Structure, Damage, and Cancer	Graduate-level course, 3 sessions in Spring Semester (2 hours each)
------	--	---

### **Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)**

2005	Epidermal Growth Factor in Clinical Oncology Medical students, residents and fellows in hematology/oncology	University of New Mexico (UNM) One-hour lecture
2006	American Society of Clinical Oncology (ASCO) Lung Cancer Update Residents and fellows in hematology/oncology	UNM On- hour lecture
2007	ASCO Lung Cancer Update Residents and fellows in hematology/oncology	UNM One-hour lecture
2008	Esophageal Cancer Residents and fellows in hematology/oncology	UNM One-hour lecture
2009	Head and Neck Cancer Residents and fellows in hematology/oncology	UNM One-hour lecture
2010	ASCO Lung Cancer Update Residents and fellows in hematology/oncology	UNM One-hour lecture
2010	Cancer Survivorship Residents and fellows in hematology/oncology	UNM One-hour lecture
2010	Small Cell Lung Cancer Residents and fellows in hematology/oncology	UNM One-hour lecture
2011	Small Cell Lung Cancer Residents and fellows in hematology/oncology	UNM One-hour lecture
2013	Cancer Detection, Cancer Prevention Residents and fellows in hematology/oncology	UK One-hour lecture
2013	Regulatory Aspects of New Drug Development Graduate Students	UK One-hour lecture
2013	Metastatic Carcinoma of Unknown Primary Site Residents and fellows in hematology/oncology	UK One-hour lecture
2014	Advanced Common Urologic Malignancies Urology faculty and residents	UK One-hour lecture

### **Clinical Supervisory and Training Responsibilities**

1998—2005	Fellows Continuity Clinic Preceptor / University of Texas Medical Branch, Galveston, TX	One half-day clinic session every other week
2005-2011	Fellows Continuity Clinic Preceptor / University of New Mexico, Albuquerque, NM	Four half-day clinic sessions every 4-5 months
2014	Fellows Continuity Clinic Preceptor/ University of Kentucky, Lexington, KY	Four half-day clinic sessions every four months
2014--present	Fellows Continuity Clinic Preceptor / DFCI at St. Elizabeth's Medical Center	One half-day session every week

2014—present	Inpatient Oncology Consult Attending / DFCI at St. Elizabeth's Medical Center	One week each month
2014—present	Outpatient Oncology Attending/ DFCI at St. Elizabeth's Medical Center	Seven half-days each week

### **Formally Supervised Trainees and Faculty**

2003–2008	Meera Ravindranathan, MD/ Assistant Professor of Medicine, University of New Mexico (currently in private practice in San Diego, CA) Mentor—Published three manuscripts, including one in <i>Journal of Clinical Oncology</i> and <i>Leukemia</i>
2006—present	M. Houman Fekrazad, MD / Assistant Professor of Medicine, University of New Mexico (currently promoted to Associate Professor at City of Hope, Duarte, CA) Mentor—Published seven manuscripts, including one in <i>Journal of Clinical Oncology</i> and <i>Cancer Chemotherapy and Pharmacology</i> , and one book chapter
2007—2014	Julie E. Bauman, MD, MPH / Assistant Professor of Medicine University of New Mexico (recently promoted to Associate Professor at the University of Pittsburgh, PA) Mentor—Published five manuscripts, including <i>Cancer Chemotherapy and Pharmacology</i> , <i>Oral Oncology</i> and <i>BMC Cancer</i> , and one book chapter

### **Local Invited Presentations**

No presentations below were sponsored by outside entities.

1999--2004	Thoracic Oncology Multidisciplinary Tumor Board, University of Texas Medical Branch (Galveston; weekly)
2005	Lung Cancer / Grand Rounds Department of Medicine, University of New Mexico
2010	Side Effects of Cancer Therapy/ Grand Rounds Department of Medicine, University of New Mexico
2011	Targeted Therapy of Lung Cancer / Grand Rounds Department of Medicine, University of Kentucky
2012	Side Effects of Cancer Therapy / Grand Rounds Department of Medicine, University of Kentucky
2012—2014	Thoracic Oncology Multidisciplinary Tumor Boards, University of Kentucky
2012—2014	Genitourinary Oncology Multidisciplinary Tumor Boards, University of Kentucky
2015	Baptist Health Grand Rounds, Madisonville, KY

## **Report of Regional, National and International Invited Teaching and Presentations**

### **Invited Presentations and Courses**

Those presentations below sponsored by outside entities are so noted and the sponsor is identified.

#### **Regional**

2013 Targeted Therapy of Lung Cancer / Grand Rounds  
Marshall University (Genentech, Inc.)

#### **National**

2007 American Society of Clinical Oncology Update  
Physician's Education Resource (CME program)  
**Four presentations:** Albuquerque, NM; New Haven, CT; Houston, TX; Beaumont, TX

2008 Lung Cancer Treatment Options  
Physician's Education Resource (CME program)  
**Three presentations:** Denver, CO; Houston, TX; Beaumont, TX

2009 American Society of Clinical Oncology Update  
Physician's Education Resource (CME program)  
Albuquerque, NM

2011 Targeted Therapy of Lung Cancer / Grand Rounds  
Tufts University Medical School, Boston, MA

2015 Immunotherapy in Solid Tumor Oncology / Grand Rounds  
Madisonville, KY

## **Report of Clinical Activities and Innovations**

### **Practice Activities**

1991—1996	Ambulatory Care and Inpatient Care	Gastrointestinal Oncology; University of Texas MD Anderson, Houston	Three full clinic sessions per week; 8 inpatient weeks/year
1998—2005	Ambulatory Care and Inpatient Care	Medical Oncology, University of Texas Medical Branch, Galveston	Three full clinic sessions per week; 4 inpatient months/year
2005—2011	Ambulatory Care and Inpatient Care	Medical Oncology; University of New Mexico,	Three full clinic sessions per week; 3 inpatient months/year
2011—2014	Ambulatory Care and Inpatient Care	Medical Oncology; University of Kentucky, Lexington, KY	Four full clinic sessions per week; 3 inpatient months/year
2014—2015	Fellows Continuity Clinic Preceptor	DSCI at St. Elizabeth's Medical Center, Brighton,	One half-day session per week

2014—2015	Inpatient Oncology Consult Attending	MA DFCI at St. Elizabeth's Medical Center	One week per month
2014—2015	Outpatient Oncology Attending	DFCI at St. Elizabeth's Medical Center	Seven half-day sessions per week
2014—2015	Outpatient Oncology	DFCI-Longwood, Boston, MA	Two half-day sessions per week
2015	Outpatient Attending Hematology/Oncology (locum tenens)	Baptist Health, Madisonville, KY	10 half-day sessions/week
2015	Inpatient Attending Hematology/Oncology (locum tenens)	Baptist Health, Madisonville, KY	Seven days/week

### **Clinical Innovations**

UTMB (1998) and UNM Cancer Center (2005) Multidisciplinary Thoracic Oncology Clinics

The initiation of these clinics signaled the first truly multidisciplinary clinics in either institution. Such clinics served two purposes:

(1) to facilitate patient care by bringing together all of the practitioners who may be able to provide real-time input into treatment decisions (thus decreasing time to initiate treatments as indicated); enhance patient safety by facilitating communication among providers; and develop, implement and follow treatment algorithms

(2) to enhance clinical research in thoracic malignancies by fostering the development of investigator-initiated clinical trials, as well as the review of sponsored clinical trials from outside the institutions, and increase the accrual of patients to such potential trials. Such clinics also significantly increased patient satisfaction.

New Mexico Cancer Care Alliance (NMCCA) (2005-2011) and University of Kentucky Markey Cancer Center Affiliate Network (UKMCCAN)

Both of these networks were begun before my recruitment to either institution; however, my efforts led to an increase in membership and the assumption of new roles for each. In both settings, the purpose was to deliver cancer care closer to home, in the neighborhoods and smaller towns at a distance from the cancer center.

My addition was to facilitate the dissemination of clinical trials through the NMCCA for participation in the offices and clinics of NMCCA members. Furthermore, the NMCCA members formed the scientific review committee for all oncology clinical protocols for both the Alliance and the UNM Cancer Center, making the Alliance members vested partners in the design and delivery of clinical research throughout New Mexico.

The UKMCCAN was not designed for clinical research, as many of its members belong to the Kentucky Clinical Trials Network, a state-funded entity. However, what had begun as an organization designed to put providers



in some of the clinics (UK staffed three such sites) and to enhance referrals to UK for complicated cases, developed into an organization responsible for the provision of provider and lay education, to implement quality improvement initiatives at the sites, and to participate in translational cancer research efforts.

## **Report of Education of Patients and Service to the Community**

### **Educational Material for Patients and the Lay Community**

No educational materials below were sponsored by outside entities.

#### **Books, monographs, articles and presentations in other media**

2007	Lung Cancer	Interviewee	Local morning TV news spot, Albuquerque, NM
2011	Lung Cancer	Interviewee	Local Sunday morning radio interview, Lexington, KY

#### **Patent Educational Material**

2009	Lung Cancer	Co-author	Patient education pamphlet, University of New Mexico
------	-------------	-----------	---

## Report of Scholarship

### Peer reviewed publications in print or other media

#### ▪ Research investigations

1. Lew Y, **Jones DV**, Mars WM, Evans D, Byrd D, Frazier ML. Expression of elongation factor-1 gamma-related sequence in human pancreatic cancer. *Pancreas*. 1992; 7(2):144-52,.
2. Chi K, **Jones DV**, Frazier ML. Expression of an elongation factor 1 gamma-related sequence in adenocarcinomas of the colon. *Gastroenterology* 1992;103(1):98-102,.
3. **Jones DV**, Patt YZ. Regional therapy of metastatic liver disease. *J Infusional Chemother* 1992; 2:115-23.
4. **Jones DV Jr**, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL. Phase II study of didemnin B in advanced colorectal cancer. *Invest New Drugs* 1992; 10(3):211-3.
5. **Jones DV Jr**, Patt YZ, Ajani JA, Abbruzzese J, Carrasco CH, Charnsangavej C, Levin B, Wallace S. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. *Cancer* 1993;72(9):2560-3.
6. **Jones DV Jr**, Ajani JA, Winn RJ, Daugherty KR, Levin B, Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. *Cancer Invest* 1993; 11(6):667-9.
7. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, **Jones DV Jr**, Markowitz AB, Abbruzzese JL, Bready B, Levin B. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. *J Clin Oncol* 1994; 12(11):2296-300.
8. **Jones DV Jr**, Sugarman SM, Markowitz A, Levin B, Abbruzzese JL, Evans DB, Charnsangavej C, Smith R, Patt YZ. Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. *Oncol Rep* 1995; 2:1121-23.
9. **Jones DV Jr**, Daugherty KR, Abbruzzese JL. A Phase I clinical trial of a protracted continuous infusion of 5-fluorouracil with oral folinic acid in patients with unresectable adenocarcinoma of the colon or rectum. *Int J Oncol* 1995; 7:191-4.
10. Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, **Jones D**, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. *Am J Clin Oncol* 1995; 18(5):436-8 .
11. **Jones DV Jr**, Winn RJ, Brown BW, Levy LB, Pugh RP, Wade JL 3rd, Gross HM, Pendergrass KB, Levin B, Abbruzzese JL. Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer. *Cancer* 1995; 76(10):1709-14.

12. Moore DF Jr, Pazdur R, Sugarman S, **Jones D**, Lippman SM, Bready B, Abbruzzese JL. Pilot phase II trial of 13-cis-retinoic acid and interferon-alpha combination therapy for advanced pancreatic adenocarcinoma. *Am J Clin Oncol* 1995;18(6):525-7.
13. Patt YZ, **Jones DV Jr**, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. *J Clin Oncol* 1996; 14(8):2311-5.
14. **Jones DV Jr**, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. *J Clin Oncol* 1996; 14(8):2306-10.
15. Patt YZ, Hoque A, Lozano R, Pazdur R, Chase J, Carrasco H, Chuang V, Delpassand ES, Ellis L, Curley S, Roh M, **Jones DV Jr**. Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. *J Clin Oncol* 1997; 15(4):1432-8 .
16. **Jones DV Jr**, Chase J, Roh M, Hohn DC, Curley S, Smith R, Hoque A, Patt YZ. A phase I evaluation of chronotropic delivery of floxuridine by hepatic arterial infusion in patients with metastatic colorectal cancer. *Oncol Rep* 1996; 3:391-5 .
17. **Jones DV Jr**, Wu E, Manire M, Frazier ML. Cis-acting elements required for expression of the nonspecific cross-reacting antigen gene in colorectal carcinoma, *Gastroenterology*1997; 112(3):776-82.
18. Vadhan-Raj S, Verschragen CF, Bueso-Ramos C, Broxmeyer HE, Kudelka AP, Freedman RS, Edwards CL, Gershenson D, **Jones D**, Ashby M, Kavanagh JJ. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. *Ann Int Med* 2000; 132(5):364-68. .
19. Saleh MN, Sugarman S, Murray J, Ostroff JB, Healey D, **Jones D**, Daniel CR, LeBherz D, Brewer H, Onetta N, LoBuglio AF. Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors. *J Clin Oncol* 2000; 18(11):2282-92.
20. Linker CA, Wolfe SN, Stein R, Herzig R, Lynch J, Fay J, Maharaj D, Ashby MA, **Jones DV**, Benyunes MC, Champlin RB. A phase II trial of recombinant human thrombopoietin in patients undergoing stem cell mobilization and rescue after dose-intensive therapy. *Biology of Blood & Marrow Transplantation* 2000; 6(1):25-34.
21. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, **Jones D**, Appelbaum FR, Champlin R. A phase I trial of recombinant human thrombopoietin (rhTPO) in patients with delayed platelet recovery after hematopoietic stem cell transplantation. *Biology of Blood & Marrow Transplantation* 2000; 6(1):25-34.
22. Wolff SN, Stein R, Herzig R, Lynch J, Ashby MA, **Jones DV**, Fay J. A phase I trial of recombinant human thrombopoietin in patients undergoing dose-intensive therapy and

autologous bone marrow transplant for breast cancer. *Bone Marrow Transplantation* 2001; 27(3):261-8 .

23. J. Gajewski, G. Rondon, M. Donato, P. Anderlini, M. Korbling, M. Benyunes, **D. Jones**, M. Ashby, S. Hellman, A. Durett, J. Lauppe, D. Geisler, I. Braunschweig, I. Khouri, S. Giralt, B. Andersson, N. Ueno, and R. Champlin. Use of Thrombopoietin for Peripheral Blood Progenitor Cell Mobilization. *Biol Blood Marrow Transplant* 2002;8(10):550-6
24. Linker C, Anderlini P, Herzig R, Christiansen N, Somlo G, Bensinger W, Fay J, Lynch JP, Goodnough LT, Ashby M, Benyunes MC, **Jones DV**, Yang TA, Miller LL, Weaver C. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. *Biol Blood Marrow Transplant* 2003; (6):405-13.
25. Spell DW, **Jones DV**, Bessman JD: The value of a complete blood count in predicting cancer of the colon. *Cancer Detect Prev* 2004;28(1):37-42.
26. Haque AK, Au W, Cajas-Salazar N, Khan S, Ginzl AW, **Jones DV**, Zwischenberger JB, Xie J. CYP2E1 polymorphism, cigarette smoking, p53 expression, and survival in non-small cell lung cancer: a long term follow-up study. *Appl Immunohistochem Mol Morphol* 2004; 12(4):315-22.
27. Du XL, **Jones DV**, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. *J Gerontol A Biol Sci Med Sci*. 2005 Sep;60(9):1137-44.
28. Hoff PM, Wolff RA, Xiong H, **Jones D**, Lin E, Eng , Dutta A, Bogaard KR, Abbruzzese JL. Phase II Trial of Combined Irinotecan and Oxaliplatin Given Every Three Weeks to Patients with Metastatic Colorectal Cancer, *Cancer*, 2006 May 15;106(10):2241-6.
29. Chi S, Huang S, Li C, Zhang X, He N, Bhutani MS, **Jones D**, Castro CY, Logrono R, Haque A, Zwischenberger J, Tying SK, Zhang H, Xie J. Activation of the hedgehog pathway in a subset of lung cancers. *Cancer Lett*. 2006 Nov 28;244(1):53-60.
30. Tai P, Chapman J-A W, Yu E, **Jones D**, Lee S-J. Disease-specific survival for limited-stage small-cell lung cancer affected by statistical method of assessment. *BMC Cancer*, 7:31 (20 Feb 2007). No page numbers (online only): <http://www.biomedcentral.com/1471-2407/7/31>.
31. **Jones DV**, Sanati S, Haque A, Freeman D, Kessel I, Zwischenberger J, Xie J. The Expression Of Signal Transduction Proteins And Their Relationship To Clinical Findings In Patients With Nonsmall Cell Lung Cancer. *Internet J Oncol* 2007; 4;(1). No page numbers (on-line only)
32. Sagar B, Estaphan F, Spell DW, Klementich F, **Jones, Jr. DV**. A Pilot Phase II Study Of Capecitabine With Carboplatin In Patients With Advanced Nonsmall Cell Lung Cancer. *Internet J Oncol* 2009; 6 (1).
33. **Jones DV**, Schroeder T, Verschraegen C. Toxicity of a combination of topotecan with external beam mediastinal radiation; Results of a Phase I study. *J Thoracic Oncol* 2012 Dec;7(12):e44-5. doi: 10.1097/JTO.0b013e3181cf32c8.

34. Sandler A, Graham C, Baggstrom M, Herbst R, Zergebel C, Saito K, **Jones D**. An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer. *J Thorac Oncol*. 2011 Aug;6(8):1400-6. doi: 10.1097/JTO.0b013e31820d7805
35. Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, **Jones D**, Szakacs, Govindan R. Multicenter Phase II Trial of Motexafin Gadolinium and Pemetrexed for Second-Line Treatment in Patients with Non-Small Cell Lung Cancer. *J Thoracic Oncol*. 2011 Apr;6(4):786-9. doi: 10.1097/JTO.0b013e31820a443f.
36. Bauman J, Verschraegen C, Belinsky S, Muller C, Rutledge T, Fekrazad MH, Ravindranathan M, Lee S-J, **Jones D**. A Phase I Study Of 5-Azacytidine And Erlotinib In Advanced Solid Tumor Malignancies. *Cancer Chemotherapy and Pharmacology*. 2012 Feb;69(2):547-54. doi: 10.1007/s00280-011-1729-2.
37. Bauman JE, Eaton KD, Wallace SG, Carr LL, Lee S-J, **Jones, Jr. DV**, Arias-Pulido H, Cerilli LA, Martins RG. A Phase II Study of Pulse Dose Imatinib Mesylate and Weekly Paclitaxel in Patients Aged 70 and Over with Advanced Non-Small Cell Lung Cancer. *BMC Cancer* 2012 Oct 3;12:449. doi: 10.1186/1471-2407-12-449.
38. Bauman JE, Aria-Pulido H, Lee S-J, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, **Jones, Jr., DV**, Chung CH. A Phase II Study of Temsirolimus and Erlotinib in Patients with Recurrent and/or Metastatic, Platinum-Refractory Head and Neck Squamous Cell Carcinoma. *Oral Oncol*. 2013 May;49(5):461-7. doi: 10.1016/j.oraloncology.2012.12.016.
39. Brown KC, Perry HE, Lau JK, **Jones DV**, Pulliam JF, Thornhill BA, Crabtree CM, Luo H, Chen YC, Dasgupta P. Nicotine induces the upregulation of the alpha7-nicotinic receptor ( $\alpha 7$ -nAChR) in human squamous cell lung cancer cells via the Sp1/GATA pathway. *J Biol Chem*. 2013 Nov 15;288(46):33049-59. doi:10.1074/jbc.M113.501601
40. Bauman J, Shaheen M, Verschraegen CF, Belinsky SA, Houman Fekrazad M, Lee FC, Rabinowitz I, Ravindranathan M, **Jones DV Jr** . A phase I protocol of hydralazine and valproic acid in advanced, previously treated cancers. *Transl Oncol*. 2014; 7(3): 349–354. doi: 10.1016/j.tranon.2014.03.001.
41. Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxon K, Jones D, George Jr. TJ, Hromas R. Synthetic lethality in malignant pleural mesothelioma With PARP1 inhibition. *Cancer Chemother Pharmacol*. Print online 7-27-2017. DOI 10.1007/s00280-017-3401-y

▪ Other peer-reviewed publications

1. **Jones DV Jr**, Cleary K Levin B. Sarcomatoid carcinoma of the gallbladder: report of two cases and review of the literature. *Cancer Bull*. 44:341-5, 1992.

2. **Jones DV Jr**, Samaan NA, Sellin RV, Ajani JA. Metastatic glucagonoma: clinical response to a combination of 5-fluorouracil and alpha-interferon. *Am J Med.* 93(3):348-9, 1992.
3. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H, **Jones DV**, Levin B. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: effects of hepatitis B and C viral infection on drug toxicity and patient survival. *J Clin Oncol.* 12:1204-11, 1994.
4. **Jones DV**, Patt YZ. Treatment of hepatocellular carcinomas. *New Perspectives in Cancer Diagnosis and Management.* 3:14-23, 1995.
5. **Jones DV Jr**, Lawrence DD, Patt YZ. Percutaneous transcatheter arterial embolization for hypersplenism. *Ann Intern Med.* 1995 Nov 15;123(10):810-1.
6. **Jones DV Jr**, Ashby M, Vadhan-Raj S, et al. Recombinant human thrombopoietin: clinical development. *Stem Cells* 16(suppl 2):199-206, 1998.
7. Osborne C, LeBouef H, **Jones Jr, DV**. Isotretinoin therapy of respiratory papillomatosis. *Ann Int Med.* 132 (12): 1007, 2000.
8. **Jones, DV**. Interleukin 11: A Promising Pleiotropic Cytokine. *Thrombocytopenia in Oncology*, Volume 1, No. 2, 1-10, 2000.
9. Spell DW, Velagelati GVN, **Jones DV**, Velasquez WS: Translocation t(15;17) and Trisomy 21 Associated with the Microgranular Variant of Acute Promyelocytic Leukemia. *Cancer Genet Cytogenet*; 132: 75-7, 2001.
10. Boroumand N, Raja V, **Jones DV**, Haque A. SYT-SSX2 Variant of Primary Pulmonary Synovial Sarcoma with Focal CD117 (c-KIT) Immunoexpression and a Poor Clinical Outcome. *Arch Path Lab Med*;127: e201-e204. 2003
11. Spell DW, Estephan FF, Lin JT, **Jones DV**. Epiphora Induced by Intermittent Docetaxel (Taxotere) in Patients with Non-Small Cell Lung Cancer. *Cancer Investigation*; 21(4):550-552, 2003
12. Logrono R, **Jones DV**, Faruqi S, Bhutani MS. Recent advances in cell biology, diagnosis, and therapy of gastrointestinal stromal tumor (GIST). *Cancer Biol and Ther*;3(3):251-8, 2004.
13. Culp L, Pou A, **Jones DV**, Bayouth, Sanguineti G. A case of radiation recall mucositis associated with docetaxel. *Head Neck* 26(2): 197-200, 2004
14. Bhutani M, **Jones Jr. DV**, Zwischenberger JB. Endoscopic ultrasound-guided fine-needle aspiration staging of lung cancer: Is it time to go beyond cytology? (Editorial). *Chest* 127(2): 418-420, 2005.
15. Estephan FF, Elghetany T, Zwischenberger J, Berry M, **Jones Jr. DV**. Complete remission with anti-CD20 therapy for unicentric, non HIV-associated, hyaline-vascular type, Castleman's disease. *Cancer Invest.* 2005;23(2):191

16. Archie V, Kauh J, **Jones DV Jr**, Cruz V, Karpeh MS Jr, Thomas CR Jr. Gastric cancer: Standards for the 21st century. *Crit Rev Oncol Hematol*. 2006 Feb;57(2):123-31.
17. Fekrazad MH, Ravindranathan M, **Jones, Jr DV**. Response Of Intracranial Metastases To Erlotinib Therapy. *J Clin Oncol*. 2007 Nov 1;25(31):5024-6.
18. Ravindranathan M, Klementich F, **Jones Jr DV**. Potential Interaction of Chemotherapy And Gefitinib In The Induction Of Hematologic Neoplasia. *Leukemia* 2007 Dec;21(12):2546-7.
19. Fekrazad MH, Eberhardt S, **Jones DV**, Lee F-C. Development of BOOP with platinum-based chemotherapy for metastatic rectal cancer. *Clin Colorectal Cancer*. 2010 Jul;9(3):177-8.
20. Fekrazad MH, **Jones DV**. Localized Chemotherapy Delivery: A Brief Review. *HCPLive*. May 14, 2010. [http://www.hcplive.com/publications/oncng-Oncology/2009/October\\_2009/A\\_Brief\\_review\\_1009](http://www.hcplive.com/publications/oncng-Oncology/2009/October_2009/A_Brief_review_1009)
21. Bauman J, **Jones DV**. Hedgehog inhibitors: Hype or hope?—Invited review: *OncLive*. May 19, 2010. [http://www.onclive.com/publications/Oncology-live/2009/December2009/Hedgehog\\_Signal\\_Inhibition\\_1209](http://www.onclive.com/publications/Oncology-live/2009/December2009/Hedgehog_Signal_Inhibition_1209)
22. **Jones DV**, Fekrazad MH, Bauman JE. Human Papilloma Virus-Induced Head and Neck Cancer. *Otolaryngology* 2013;S2:002.

**Non-peer reviewed scientific or medical publications/materials in print or other media**

1. **Jones DV Jr**, Levin B, Salem P. Primary small bowel lymphomas. In: *Gastrointestinal Disease, Fifth Edition*. Sleisenger M and Fordtran J (eds.). Philadelphia: W.B. Saunders Co. pps. 1378-1393; 1992.
2. **Jones DV Jr**, Patt YZ. Regional therapy for hepatic malignancies. In: *Therapiekonzepte Onkologie, 2nd Edition*. Seeber/Schütte (eds.). Berlin-Heidelberg-New York: Springer-Verlag, 1995. pps. 594-625.
3. **Jones DV Jr**. Liposomal targeting strategies. In: *Applications for liposomes in human malignancy: Current status and future directions*. Sugarman S (ed.). Austin, Texas: R. G. Landes Co., 1995. pps. 135-152.
4. **Jones DV Jr**. Liposomes in nucleic acid transfection. In: *Applications for liposomes in human malignancy: Current status and future directions*. Sugarman S (ed.). Austin, TX: R. G. Landes Co., 1995. pps. 153-171.
5. Salem PA, **Jones DV Jr**. Treatment of malignant neoplasms of the mucosa-associated lymphoid tissues (MALT). In: *The Non-Hodgkin Lymphomas, Second Edition*. Magrath I (ed.). New York: Oxford University Press, 1997. pps. 989-1005,
6. Ellis LM, **Jones DV Jr.**, Chiao PJ, Pellis NR. Tumor biology. In: *Surgery: Scientific Principles and Practice, Second Edition*. Greenfield LJ, Mulholland MW, Oldham KT, Zelenock GB, Lillemoe KD (eds.). Philadelphia: Lippincott-Raven Publishers, 1997. pps. 455-505.

7. **Jones DV Jr**, Levin B, Salem P. Intestinal Lymphomas, including immunoproliferative small intestinal disease. In: *Gastrointestinal Disease*. Sixth Edition. Sleisenger M, Scharschmidt BF, Fordtran J (eds.). Philadelphia: W.B. Saunders Co., 1998. pps. 1844-57.
8. **Jones DV Jr**, Skibber J, Levin B. Adenocarcinoma and other small intestinal neoplasms, including benign tumors. In: *Gastrointestinal Disease*, Sixth Edition. Sleisenger M, Scharschmidt BF, Fordtran J (eds.). Philadelphia: W.B. Saunders Co., 1998. pps. 1858-64.
9. Brower ST, Hoff PM, **Jones DV Jr**, Cunningham JD, Myerson RJ. Pancreatic cancer, hepatobiliary cancer, and neuroendocrine cancers of the GI tract. In: *Cancer Management: A multidisciplinary approach*. Second edition. Pazdur R, Coia LR, Hoskins WJ, Wagman LD (eds.). Huntington, NY: PRR, Inc., 1998. pps. 113-148.
10. **Jones DV Jr**. Chemotherapeutic treatments for hepatocellular carcinoma. In: *Liver Cancer*. Curley SA (ed.). New-York: Springer-Verlag, 1998. pp. 53-68.
11. **Jones DV Jr**. Gene therapy in hepatocellular carcinoma. In: *Liver Cancer*. Curley SA (ed.). New-York: Springer-Verlag, Inc., 1998. pp. 230-45.
12. Curley SA, **Jones DV**. Management of hepatocellular carcinoma. In: *Neoplasms of the Digestive Tract: Imaging, Staging and Management*. MA Meyers (ed.). Philadelphia: Lippincott-Raven Publishers, 1998. pps. 347-60.
13. Bouvet J, Janjan NA, **Jones DV**, Ellis LM. Small Bowel Tumors. In: Torosian, M.H. (ed). *Integrated Cancer Management: Surgery, Medical Oncology and Radiation Oncology*. New York: Marcel Dekker, Inc., 1999. pp. 106-132.
14. Velasco MR, Concepcion L, **Jones DV, Jr**. Primary Gastric and Intestinal Lymphomas. In: *Gastrointestinal Oncology, Principles and Practices*. Kelsen DP, Daly JM, Kern SE, Levin B, Tepper JE (eds). Philadelphia, PA: Lippincott Williams & Wilkins, 2002. pp. 899-919.
15. Fekrazad MH, Sanaei O, Bauman JE, **Jones DV, Jr**. Brain Metastases From Non-Small Cell Lung Cancer: Clinical Benefits Of Erlotinib And Gefitinib. In: Hayat M, ed. *Brain Metastases: Epidemiology, Biology, and Therapy of the Disease*. Volume 1. Elsevier/Academic Press. In Press, 2014.
16. Dittrich C, Kosty M, Jezdic S, Pyle D, Berard, R, Bergh J, El-Saghir N, Lotz J, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, **Jones DV**, Jost L, Keilholz U, Khan S, Kiss A, Köhne C, Kunstfeld R, Lenz H, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll H, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M,



Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. (2016). ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open, 1(5), e000097. Accessed October 04, 2016. <http://dx.doi.org/10.1136/esmoopen-2016-000097>.

## **Narrative Report**

Although my early focus was basic research, my interests have always been stronger in clinical medicine and clinical research. My time in bench-based research was very valuable, providing me with crucial insight into the conduct of basic research, and how it applies to real-world clinical situations.

Most of my clinical work has been with patients with solid tumors, primarily lung and GI tract malignancies. I had inpatient and outpatient duties at two campuses of UT, as well as at UNM and UK, often with underserved populations. My expertise with medical and surgical teams will prove an advantage in my new position.

I created multi-disciplinary clinics at UTMB, UNM, and UK. While at UNM, in collaboration with Pulmonary Medicine, Thoracic Surgery, and Radiation Oncology colleagues, I designed care algorithms for patients with suspected or diagnosed lung neoplasms. Reviewed biennially in our Thoracic Oncology Multidisciplinary Working Group, these pathways helped determine novel care needs, monitor routine practices, and identify areas for clinical research. The multi-disciplinary treatment plans I inaugurated at UK for thoracic cancers have proven a model for other tumor-specific care groups there. In addition to my duties with lung cancer patients, I helped to fill clinical needs by staffing the urologic cancer multi-disciplinary clinic, as well as a general community oncology clinic, while at UK.

In recent bench and clinical studies evaluating alterations in signal transduction and epigenetic changes in lung cancer as markers of carcinogenesis, and therapeutic targets for prevention and therapy, I worked closely with basic researchers across several campuses. I have designed 3 phase I-II trials of novel signal transduction inhibitors in lung cancer, and I intend to continue to participate in clinical and translational research in my leadership role. My academic focus will be in thoracic neoplasia—particularly, design and conduct of translational research efforts that may lead to the evaluation of novel treatment regimens for established disease with signal transduction inhibitors, as well as development of chemoprevention regimens based upon signal transduction inhibitors and chromatin modifying agents. I will continue my interest in novel drug development for lung and other cancers through collaboration with the basic researchers of the university.

I was Fellowship Director and both Assistant and Interim Division Chief for several years at the UT Medical Branch, and Interim Division Chief at UK for a year. I also served as the Medical Director for the UNM Cancer Center Clinical Protocol, Data Management and Informatics group, which was responsible for regulatory reporting and data coordination functions for 320+ clinical trials (an increase from ~150 trials at my arrival), and all cancer-related basic research trials. In addition, I have been Medical Director for 2 community-based regional networks, which offered opportunities for clinical research, as well as healthcare provider and lay outreach and education.

I have coordinated study sessions for fellows and residents based upon boards review subjects, as well as clinical case-based (classroom-to-bedside) teaching sessions. I have clinically supervised students and trainees, and will do so in my new role. I have also served as a mentor at UTMB, UNM, and UK,

including mentoring the UK junior faculty member recruited to care for patients with urologic malignancies—with the plan that he would eventually lead the clinical and translational research program for the university's cancer center. We reviewed the clinical trials menu for urologic malignancies, identifying opportunities and following rates of accruals to studies. I helped him build contacts with basic researchers on campus, as well as industry-based scientists, to assist him in design and conduct of trials. I will continue mentoring junior faculty and trainees, matching areas of interest with individual strengths, while increasing clinical efficiency so that faculty and fellows will have time to devote to academic pursuits. The goal will be to develop junior clinician-scientists capable of designing, conducting, and analyzing investigator-initiated studies.

I have demonstrated a strong effort across multiple academic areas, especially in my clinical Area of Excellence and my administrative Significant Supporting Activity. I have also made major contributions in clinical and translational research, and have realized positive impacts in education on campus and throughout the community.